Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for ESVEA and High Embolism Risk
NCT05487950Phase 4Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of rivaroxaban in Supraventricular extrasystole (SVES), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
Supraventricular extrasystole (SVES)
Beyond the preview
Go deeper on NCT05487950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487950.